ArticleBreast cancer research and treatment2022

Characterizing experiences of non-medical switching to trastuzumab biosimilars using data from internet-based surveys with US-based oncologists and breast cancer patients.

Elizabeth Lerner Papautsky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.